Development of an Antiepileptogenesis Drug Screening Platform: Effects of Everolimus and Phenobarbital

Objective The kainic acid (KA)-induced status epilepticus (SE) model in rats is an etiologically-relevant animal model of epileptogenesis. Just as in patients, who develop temporal lobe epilepsy (TLE) following SE, this rat model of KA-induced SE very closely recapitulates many of the clinical and pathological characteristics of human TLE that arise following SE or another neurological insult. Spontaneous recurrent seizures (SRS) in TLE can present after a latent period following a neurological insult (TBI, SE event, viral infection, etc.). Moreover, this rat model of TLE is ideally suited for preclinical studies to evaluate the long-term process of epileptogenesis and screen putative disease-modifying/antiepileptogenic agents. This report details the pharmacological characterization and methodological refinement of a moderate-throughput drug screening program using the post KA-induced SE model of epileptogenesis in male Sprague Dawley rats to identify potential agents that may prevent or modify the onset or severity of SRS. Specifically, we sought to demonstrate whether our protocol could prevent the development of SRS, or lead to a reduced frequency/severity of SRS. Methods Rats were administered everolimus (2-3 mg/kg, P.O. commencing at 1, 2, or 24-hrs after SE onset) or phenobarbital (60 mg/kg, beginning 1 hr after SE onset). The rats in all studies (n=12/treatment dose/study) were then followed intermittently by video-EEG monitoring; i.e., 2-weeks on/2-weeks off, 2-weeks on epochs to determine latency to onset of SRS, and disease burden following SRS onset. Results While there were no adverse side effects observed in any of our studies, no treatment conferred a significant disease modifying effect, nor did any agent prevent the presentation of SRS by 6 weeks post-SE onset. Conclusions While neither phenobarbital nor everolimus administered at several time points post-SE onset prevented the development of SRS, we herein demonstrate a moderate-throughput screen for potential antiepileptogenic agents in an etiologically-relevant rodent model of TLE. Key Points Disease-modifying therapies are needed to prevent or attenuate the burden of epilepsy in at-risk individuals. We report a moderate-throughput screening protocol to identify disease-modifying agents in a rat post-kainic acid status epilepticus model. Everolimus was administered at multiple time points post-status epilepticus with no effect on spontaneous seizures up to 6 weeks later. Repeated administration of phenobarbital also did not prevent the development of spontaneous recurrent seizures up to 6 weeks post SE. While we did not identify any effect of either agent, our approach provides a moderate-throughput screen for antiepileptogenesis.

[1]  M. Barker-Haliski,et al.  Diurnal burden of spontaneous seizures in early epileptogenesis in the post‐kainic acid rat model of epilepsy , 2021, Epilepsia open.

[2]  D. Fabbro,et al.  Novel brain permeant mTORC1/2 inhibitors are as efficacious as rapamycin or everolimus in mouse models of acquired partial epilepsy and tuberous sclerosis complex , 2020, Neuropharmacology.

[3]  K. Thomson,et al.  Evaluation of subchronic administration of antiseizure drugs in spontaneously seizing rats , 2020, Epilepsia.

[4]  M. Barker-Haliski,et al.  Validated animal models for antiseizure drug (ASD) discovery: Advantages and potential pitfalls in ASD screening , 2020, Neuropharmacology.

[5]  F. Jansen,et al.  Update on Drug Management of Refractory Epilepsy in Tuberous Sclerosis Complex , 2020, Pediatric Drugs.

[6]  P. Crino Mechanistic target of rapamycin (mTOR) signaling in status epilepticus , 2019, Epilepsy & Behavior.

[7]  D. Franz,et al.  Everolimus as adjunctive therapy for tuberous sclerosis complex-associated partial-onset seizures , 2019, Expert review of neurotherapeutics.

[8]  F. Dudek,et al.  Effect of carbamazepine on spontaneous recurrent seizures recorded from the dentate gyrus in rats with kainate‐induced epilepsy , 2019, Epilepsia.

[9]  E. Aronica,et al.  mTOR dysregulation and tuberous sclerosis-related epilepsy , 2018, Expert review of neurotherapeutics.

[10]  M. Wong,et al.  Targeting the Mammalian Target of Rapamycin for Epileptic Encephalopathies and Malformations of Cortical Development , 2018, Journal of child neurology.

[11]  S. Dedeurwaerdere,et al.  Kainic Acid-Induced Post-Status Epilepticus Models of Temporal Lobe Epilepsy with Diverging Seizure Phenotype and Neuropathology , 2017, Front. Neurol..

[12]  J. Kehne,et al.  The National Institute of Neurological Disorders and Stroke (NINDS) Epilepsy Therapy Screening Program (ETSP) , 2017, Neurochemical Research.

[13]  Roy M. Smeal,et al.  Hippocampal TNFα Signaling Contributes to Seizure Generation in an Infection-Induced Mouse Model of Limbic Epilepsy , 2017, eNeuro.

[14]  Yi-Chin Lin,et al.  Everolimus is better than rapamycin in attenuating neuroinflammation in kainic acid-induced seizures , 2017, Journal of Neuroinflammation.

[15]  T. H. Sasongko,et al.  Rapamycin and rapalogs for tuberous sclerosis complex. , 2016, The Cochrane database of systematic reviews.

[16]  Lars E. Borm,et al.  Effects of rapamycin and curcumin treatment on the development of epilepsy after electrically induced status epilepticus in rats , 2016, Epilepsia.

[17]  E. Thiele,et al.  Tuberous Sclerosis Complex , 2019, Harper's Textbook of Pediatric Dermatology.

[18]  S. Jóźwiak,et al.  Role of mTOR inhibitors in epilepsy treatment , 2015, Pharmacological reports : PR.

[19]  J. French,et al.  Disease Modification in Epilepsy: From Animal Models to Clinical Applications , 2015, Drugs.

[20]  Kyle E. Thomson,et al.  A novel open-source drug-delivery system that allows for first-of-kind simulation of nonadherence to pharmacological interventions in animal disease models , 2014, Journal of Neuroscience Methods.

[21]  D. Friedman,et al.  How Clinical Development Can, and Should, Inform Translational Science , 2014, Neuron.

[22]  Francesco Brigo,et al.  Antiepileptogenesis in humans: disappointing clinical evidence and ways to move forward. , 2014, Current opinion in neurology.

[23]  W. Löscher,et al.  Searching for the Ideal Antiepileptogenic Agent in Experimental Models: Single Treatment Versus Combinatorial Treatment Strategies , 2014, Neurotherapeutics.

[24]  K. Thomson,et al.  The expression of kainate receptor subunits in hippocampal astrocytes after experimentally induced status epilepticus. , 2013, Journal of neuropathology and experimental neurology.

[25]  I. Módy,et al.  Issues related to development of antiepileptogenic therapies , 2013, Epilepsia.

[26]  D. Brody,et al.  Rapamycin Attenuates the Development of Posttraumatic Epilepsy in a Mouse Model of Traumatic Brain Injury , 2013, PloS one.

[27]  T. Grandin,et al.  AVMA Guidelines for the Euthanasia of Animals: 2013 Edition , 2013 .

[28]  J. McMahon,et al.  Rapamycin attenuates aggressive behavior in a rat model of pilocarpine-induced epilepsy , 2012, Neuroscience.

[29]  G. Brophy,et al.  Practice Variations in the Management of Status Epilepticus , 2012, Neurocritical Care.

[30]  S. Koh,et al.  Minocycline attenuates microglia activation and blocks the long-term epileptogenic effects of early-life seizures , 2012, Neurobiology of Disease.

[31]  Paul M. Vespa,et al.  Guidelines for the Evaluation and Management of Status Epilepticus , 2012, Neurocritical Care.

[32]  K. Lukasiuk,et al.  Post-treatment with rapamycin does not prevent epileptogenesis in the amygdala stimulation model of temporal lobe epilepsy , 2012, Neuroscience Letters.

[33]  N. Temkin,et al.  Antiepileptogenic Agents How Close Are We ? , 2012 .

[34]  A. Robertson,et al.  Domoic acid and human exposure risks: a review. , 2010, Toxicon : official journal of the International Society on Toxinology.

[35]  M. Wong Mammalian target of rapamycin (mTOR) inhibition as a potential antiepileptogenic therapy: From tuberous sclerosis to common acquired epilepsies , 2010, Epilepsia.

[36]  L. Zeng,et al.  The Mammalian Target of Rapamycin Signaling Pathway Mediates Epileptogenesis in a Model of Temporal Lobe Epilepsy , 2009, The Journal of Neuroscience.

[37]  N. Temkin Preventing and treating posttraumatic seizures: The human experience , 2009, Epilepsia.

[38]  W. Löscher The Pharmacokinetics of Antiepileptic Drugs in Rats: Consequences for Maintaining Effective Drug Levels during Prolonged Drug Administration in Rat Models of Epilepsy , 2007, Epilepsia.

[39]  L. Murri,et al.  Phenobarbital prophylaxis of post traumatic epilepsy , 1979, Neurological Sciences.

[40]  Philip A. Williams,et al.  Use of Chronic Epilepsy Models in Antiepileptic Drug Discovery: The Effect of Topiramate on Spontaneous Motor Seizures in Rats with Kainate‐induced Epilepsy , 2005, Epilepsia.

[41]  L. Murri,et al.  Phenobarbital in the prophylaxis of late posttraumatic seizures , 1992, The Italian Journal of Neurological Sciences.

[42]  E. Cavalheiro,et al.  New insights from the use of pilocarpine and kainate models , 2002, Epilepsy Research.

[43]  E. Bertram,et al.  Phenobarbital and MK‐801, but not phenytoin, improve the long‐term outcome of status epilepticus , 2002, Annals of neurology.

[44]  N. Temkin Antiepileptogenesis and Seizure Prevention Trials with Antiepileptic Drugs: Meta‐Analysis of Controlled Trials , 2001, Epilepsia.

[45]  N R Temkin,et al.  Antiepileptogenic agents: how close are we? , 2001, Drugs.

[46]  Y. Ben-Ari,et al.  Kainate, a double agent that generates seizures: two decades of progress , 2000, Trends in Neurosciences.

[47]  G. Holmes,et al.  Comparison of valproate and phenobarbital treatment after status epilepticus in rats , 1998, Neurology.

[48]  F. Edward Dudek,et al.  Recurrent spontaneous motor seizures after repeated low-dose systemic treatment with kainate: assessment of a rat model of temporal lobe epilepsy , 1998, Epilepsy Research.

[49]  W. Hauser,et al.  A population-based study of seizures after traumatic brain injuries. , 1998, The New England journal of medicine.

[50]  G. Holmes,et al.  Age‐Dependent Cognitive and Behavioral Deficits After Kainic Acid Seizures , 1993, Epilepsia.

[51]  G. Golarai,et al.  Alteration of long-lasting structural and functional effects of kainic acid in the hippocampus by brief treatment with phenobarbital , 1992, The Journal of neuroscience : the official journal of the Society for Neuroscience.

[52]  W. Hauser,et al.  Prevalence of Epilepsy in Rochester, Minnesota: 1940–1980 , 1991, Epilepsia.